NVST
Full HouseAI screen passEnvista Holdings Corporation · Healthcare · United States · $3.8B cap · $80.1M/day traded
$25.32 -2.0% · close 11 Nov · scored 12 Nov
Full House: Strong business, sensible price, and the market agrees.
After its 4 Nov results, analysts raised next year's EPS estimate 0.6%.
As of 12 Nov 2026, the MoatMap Score for Envista Holdings Corporation (NVST) is 88/100, ranked against 25,000+ stocks in 38 markets (Quality 67, Value 69, Momentum 53, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Envista Holdings clears the calibrated bar. All three legs are above the floor (Q57 V51 M78) and an active buyback provides the required corroboration. Nothing adverse is on file: no negative earnings revision and no insider selling. Strong momentum at M78 suggests the market is beginning to confirm the dental recovery.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT ENVISTA HOLDINGS CORPORATION
Read
Envista Holdings Corporation manufactures and distributes dental products, including consumables, equipment, and digital imaging solutions, serving dental professionals worldwide. It leverages a broad portfolio of well-known dental brands and a global sales and distribution network to maintain its competitive standing. Spun off from Danaher Corporation, Envista is a significant player in the dental industry with a focus on innovation and digital dentistry.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 2.6B | 2.6B | 2.5B | 2.7B | 1.9% | 2.9B | 2.9B | 3.0B | 4.4% |
| EPS | 2.11 | 1.49 | -0.60 | -6.50 | 0.28 | -39.6% | 3.85 | 0.36 | 0.39 | 18.4% |
| Shares | — | 163.2M | 171.5M | 172.2M | 163.8M | +0.4% | 160.3M | — | — | — |
| Debt | — | 1.5B | 1.7B | 1.5B | 1.6B | 1.5% | 1.6B | — | — | — |
| Equity | — | 4.2B | 4.2B | 2.9B | 3.1B | -9.6% | — | — | — | — |
| Op CF | — | 182.7M | 275.7M | 336.5M | 275.7M | 14.7% | 301.8M | — | — | — |
| Inv CF | — | -657.3M | -62.4M | -54.6M | -51.1M | — | — | — | — | — |
| Fin CF | — | 12.5M | 118.9M | -103.7M | -170.9M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 53% of stocks we rank over the past year (volatility 40% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVST are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| NVST | Envista Holdings Corporation(you) | $3.8B | 88 |
| MMSI | Merit Medical Systems, Inc. | $5.6B | 88 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
| MMED | MiniMed Group, Inc. | $5.2B | 60 |
| AVTR | Avantor, Inc. | $11.7B | 74 |
| ATR | AptarGroup, Inc. | $8.0B | 65 |
| BAX | Baxter International Inc. | $13.1B | 74 |
Peer medians: ROE -31.0% · P/E 26.3x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.